VREX Quote, Financials, Valuation and Earnings

Nuwellis has a net margin of -0.15% compared to Varex Imaging's net margin of -63.22%. Varex Imaging's return on equity of -8.27% beat Nuwellis's return on equity of -800.59%.

Varex Imaging has a consensus price target of $21.20, signalling upside risk potential of 170.41%. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 1295.12%. Given that Nuwellis has higher upside potential than Varex Imaging, analysts believe Nuwellis is more attractive than Varex Imaging.

Varex Imaging has a beta of 0.649, which suggesting that the stock is 35.121% less volatile than S&P 500. In comparison Nuwellis has a beta of 0.510, suggesting its less volatile than the S&P 500 by 49.013%.

Varex Imaging has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Varex Imaging pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Varex Imaging quarterly revenues are $199.8M, which are larger than Nuwellis quarterly revenues of $2.3M. Varex Imaging's net income of -$300K is higher than Nuwellis's net income of -$1.5M. Notably, Varex Imaging's price-to-earnings ratio is 17.58x while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Varex Imaging is 0.39x versus 0.17x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -0.15% compared to Varex Imaging's net margin of -34.09%. Varex Imaging's return on equity of -8.27% beat Quanterix's return on equity of -11.35%.

Varex Imaging has a consensus price target of $21.20, signalling upside risk potential of 170.41%. On the other hand Quanterix has an analysts' consensus of $13.88 which suggests that it could grow by 166.83%. Given that Varex Imaging has higher upside potential than Quanterix, analysts believe Varex Imaging is more attractive than Quanterix.

Varex Imaging has a beta of 0.649, which suggesting that the stock is 35.121% less volatile than S&P 500. In comparison Quanterix has a beta of 1.351, suggesting its more volatile than the S&P 500 by 35.098%.

Varex Imaging has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Varex Imaging pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Varex Imaging quarterly revenues are $199.8M, which are larger than Quanterix quarterly revenues of $34.1M. Varex Imaging's net income of -$300K is higher than Quanterix's net income of -$11.6M. Notably, Varex Imaging's price-to-earnings ratio is 17.58x while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Varex Imaging is 0.39x versus 1.47x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -0.15% compared to Varex Imaging's net margin of -118.53%. Varex Imaging's return on equity of -8.27% beat Stereotaxis's return on equity of -139.2%.

Varex Imaging has a consensus price target of $21.20, signalling upside risk potential of 170.41%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 171.08%. Given that Stereotaxis has higher upside potential than Varex Imaging, analysts believe Stereotaxis is more attractive than Varex Imaging.

Varex Imaging has a beta of 0.649, which suggesting that the stock is 35.121% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Varex Imaging has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Varex Imaging pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Varex Imaging quarterly revenues are $199.8M, which are larger than Stereotaxis quarterly revenues of $6.3M. Varex Imaging's net income of -$300K is higher than Stereotaxis's net income of -$7.5M. Notably, Varex Imaging's price-to-earnings ratio is 17.58x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Varex Imaging is 0.39x versus 5.25x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.

TransMedics Group has a net margin of -0.15% compared to Varex Imaging's net margin of 5.64%. Varex Imaging's return on equity of -8.27% beat TransMedics Group's return on equity of 19.17%.

Varex Imaging has a consensus price target of $21.20, signalling upside risk potential of 170.41%. On the other hand TransMedics Group has an analysts' consensus of $103.14 which suggests that it could grow by 28%. Given that Varex Imaging has higher upside potential than TransMedics Group, analysts believe Varex Imaging is more attractive than TransMedics Group.

Varex Imaging has a beta of 0.649, which suggesting that the stock is 35.121% less volatile than S&P 500. In comparison TransMedics Group has a beta of 2.138, suggesting its more volatile than the S&P 500 by 113.849%.

Varex Imaging has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Varex Imaging pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

Varex Imaging quarterly revenues are $199.8M, which are larger than TransMedics Group quarterly revenues of $121.6M. Varex Imaging's net income of -$300K is lower than TransMedics Group's net income of $6.9M. Notably, Varex Imaging's price-to-earnings ratio is 17.58x while TransMedics Group's PE ratio is 79.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Varex Imaging is 0.39x versus 6.43x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.